Department of Nuclear Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):274-84. doi: 10.1007/s00259-010-1619-6. Epub 2010 Sep 17.
In children with Hodgkin's disease and non-Hodgkin's lymphoma, the ability of (18)F-fluoro-2-deoxy-D-glucose PET/CT and conventional imaging (CI) to detect malignant lesions and predict poor lesion response to therapy was assessed and compared.
A retrospective review of findings reported on PET/CT and CI was performed using a lesion-based analysis of 16 lymph node and 8 extra-nodal regions. Lesions were defined by histopathological findings or follow-up > 6 months.
The study included 209 PET/CT scans with a valid CI comparator. A total of 5,014 regions (3,342 lymph node, 1,672 extra-nodal) were analysed. PET/CT performed significantly better than CI in the detection of malignant lesions with sensitivity and specificity of 95.9 and 99.7% compared to 70.1 and 99.0%, respectively. For predicting poor lesion response to therapy, PET/CT had fewer false-positive lesions than CI. The specificity for predicting poor lesion response to treatment for PET/CT was 99.2% compared to 96.9% for CI. PET/CT was the correct modality in 86% of lesions with discordant findings.
PET/CT is more accurate than CI in detecting malignant lesions in childhood lymphoma and in predicting poor lesion response to treatment. In lesions with discordant findings, PET/CT results are more likely to be correct.
评估并比较氟-18-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（18F-FDG PET/CT）与常规影像学（CI）在检测霍奇金病和非霍奇金淋巴瘤患儿恶性病变及预测病变对治疗反应不良的能力。
采用基于病灶的分析方法，对 16 个淋巴结和 8 个结外区域的 PET/CT 和 CI 检查结果进行回顾性分析。病灶的定义为组织病理学发现或随访时间>6 个月。
本研究共纳入 209 例有有效 CI 对比的 PET/CT 扫描。共分析了 5014 个病灶（3342 个淋巴结，1672 个结外）。与 CI 相比，PET/CT 对恶性病变的检测具有更高的灵敏度（95.9%比 70.1%）和特异性（99.7%比 99.0%）。在预测病变对治疗反应不良方面，PET/CT 较 CI 假阳性病灶更少。PET/CT 预测治疗后病变反应不良的特异性为 99.2%，而 CI 为 96.9%。在表现不一致的病灶中，86%的情况下 PET/CT 结果更正确。
与 CI 相比，PET/CT 在检测儿童淋巴瘤的恶性病变和预测病变对治疗反应不良方面更准确。在表现不一致的病灶中，PET/CT 结果更可能是正确的。
